Targeting Cend1-Atp5f1b interaction rescues mitochondrial dysfunction and ameliorates ischemic brain injury Authors: Hao Li, Yi Yang, Meng Zhang, Eric Guo, Zeheng Li, Bo Wan, Zhigang Miao, Wei Ge, Gang Chen, Xingshun Xu Published: 2025 ABSTRACT Mitochondrial dysfunction is a critical contributor to neuronal damage in acute ischemic stroke (AIS), and targeting mitochondrial function represents a promising therapeutic strategy. This study unveils the pivotal role of Cend1 protein in ischemic stroke and elucidates its underlying mechanisms. Using Cend1 knockout (KO) mice, Cend1 deficiency was shown to exacerbate cerebral ischemia/reperfusion injury, as evidenced by enlarged infarct volume, worsened neurological deficits in motor coordination and grip strength, together with alterations in mitochondrial membrane potential (ΔΨm), mPTP opening, ATP content, and the activities of respiratory Complex I and V. Mechanistically, Cend1 forms dimers via conserved GXXXA motifs in its transmembrane domain to enhance ATP synthesis. Disruption of dimerization of Cend1 (such as G130P mutation) destabilized Cend1, accelerating its degradation and abolishing ATP-enhancing effects. Atp5f1b, a mitochondrial ATP synthase subunit, was found to interact with Cend1. Furthermore, screening identified the small-molecule compound Tianeptine (TNT), which stabilizes Cend1 dimers, elevates ATP levels, and confers neuroprotection in a Cend1-dependent manner. Notably, TNT’s efficacy was abolished in Cend1 KO mice, highlighting its reliance on Cend1. The findings support the Cend1/Atp5f1b interaction as a potential mitochondria-targeted mechanism, offering innovative strategies to combat ischemic stroke by enhancing bioenergetic resilience. Introduction Mitochondria are vital in cellular and organismal pathways that direct metabolism, stress responses, immunity, and cellular fate1, especially in terms of bioenergetics and apoptosis2,3. Due to their vital role in cellular function, and because mitochondrial dysfunction underlies many multifactorial diseases—especially neurological disorders such as acute ischemic stroke (AIS)—mitochondria have been regarded as promising therapeutic targets for these conditions4,5. AIS is one of the most common types of stroke caused by decreased blood flow and depleted adenosine triphosphate (ATP) production in the ischemic brain region6. The reduction of ATP triggers ischemic cascades such as membrane ion pump failure, plasma membrane depolarization, efflux of cellular potassium, and influx of sodium, calcium, chloride, and water7. Impaired ATP production after stroke was associated with mitochondrial dysfunction and increased mitochondrial degradation8. Functional mitochondria are essential in promoting neural survival and neurological improvement following ischemic stroke9–11, emphasizing the importance of maintaining mitochondrial functions as a therapeutic strategy for stroke treatment. Mitochondria are enclosed by two distinct membranes: an outer membrane and an inner membrane. The inner membrane contains cristae, which greatly increase the surface area available to membrane proteins. Cell cycle exit and neuronal differentiation 1 (Cend1), also known as BM88, is a neuron-specific single-pass transmembrane protein containing a transmembrane domain of 20 hydrophobic amino acids12,13. Previous studies have shown that Cend1 is localized to the outer mitochondrial membrane, and its deletion induces mitochondrial dysfunction14. The function of Cend1 has been shown to involve coordinating cell cycle exit and differentiation of neuronal progenitors15. To explore the role of Cend1 in the central nervous system, Cend1 knockout mice were created and showed no overt abnormalities in overall appearance or brain shape compared to wild-type mice, but in behavioral tests, Cend1-deficient mice were found to exhibit decreased motor coordination, increased anxiety-related behavior, and impaired cognitive function14,16,17. In terms of histomorphology, the researchers found Cend1 knockout mice display impaired cerebellar development16, suggesting that Cend1 may play an important role in neurodevelopment. The role of Cend1 in the neuropathophysiological context remains under investigation, although its tissue-specific expression makes it an appealing candidate for further study in ischemic stroke. This study investigated the role of Cend1 in ischemia-reperfusion injury, particularly its potential regulation of mitochondrial ATP production through interactions with other mitochondrial proteins. Furthermore, possible pharmacological interventions aimed at stabilizing the Cend1 dimer were explored, with the goal of identifying potential protective effects against ischemic brain injury. Materials and methods Reagents Cend1 antibody (#8944S; 1:5000 dilution) was obtained from Cell Signaling Technology (Danvers, MA, USA). Tom20 antibody (A19403; 1:3000 dilution) was obtained from ABclonal Technology Co., Ltd (Wuhan, China). ATP5B antibody (sc-55597; 1:1000 dilution) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). GFP antibody (ab1218; 1:1000 dilution) was purchased from Abcam (Cambridge, MA, USA). HA-Tag (26D11) antibody (M20003; 1:5000 dilution) was purchased from Abmart (Shanghai, China). β-actin antibody (FD0060; 1:10000 dilution), β-tubulin antibody (FD0064; 1:10000 dilution), and GAPDH antibody (FD0063; 1:10000 dilution) were obtained from Fude Biological Technology Co., Ltd (Hangzhou, China). Secondary antibodies for western blot analysis, including anti-rabbit lgG-HRP (111-035-003; 1:3000 dilution) and anti-mouse lgG-HRP (115-035-003; 1:3000 dilution), were purchased from Jackson ImmunoResearch Co., Ltd (West Grove, PA, USA). Anti-rabbit lgG-HRP (M21006S; 1:3000 dilution) was obtained from Abmart (Shanghai, China). Secondary antibodies for immunofluorescence were purchased from Thermo Fisher Scientific (Gaithersburg, MD, USA) and included the following: Alexa Fluor-488 donkey anti-rabbit IgG antibody (A21206; 1:200 dilution). Cell culture Primary cortical neurons were isolated from C57BL/6 fetal mice at embryonic day 16–18 (E16–18). Cortical tissues were carefully dissected, mechanically minced, and digested with 0.125% trypsin (Gibco, USA). The digestion was terminated by adding complete Dulbecco’s Modified Eagle Medium (DMEM, Gibco, USA). The resulting cell suspension was filtered and centrifuged to collect primary neurons. Cells were then seeded onto culture plates pre-coated with poly-D-lysine and initially maintained in complete DMEM for 4 hours. After this incubation, the medium was aspirated, and cells were gently rinsed with pre-warmed PBS (Biosharp, China). Finally, neurons were cultured in pre-warmed Neurobasal Medium (Gibco, USA) supplemented with 2% B-27, 0.5 mM GlutaMAX, and 50 U/mL penicillin-streptomycin (Invitrogen, USA) for up to 10 days in vitro at 37 °C under 5% CO2. Primary neurons were used because they provide a physiologically relevant model to study Cend1-dependent effects on neuronal protein dimerization and mitochondrial function, which may not be fully recapitulated in immortalized cell lines. Animals Adult male C57BL/6J mice (20-25 g) were purchased from Shanghai Jihui Laboratory Animal Care Co., Ltd. (Shanghai, China), and the Cend1 KO mice were generated from CAM-SU Genomic Resource Center (Soochow, China). All mice were allowed free access to food and water under controlled conditions (12/12 h light/dark cycle with humidity of 50 ± 10%, 22 ± 3 °C). All the experimental protocols were approved by the Ethics Committee of the Fourth Affiliated Hospital of Soochow University and its institutional animal-care committee. Every effort was made to avoid/alleviate animal pain and distress and minimize the number of animals used in the study. Middle cerebral artery occlusion/reperfusion surgery Middle cerebral artery occlusion/reperfusion (MCAO/R) was performed according to a previous description18. Mice were anesthetized with 4% isoflurane, and their anesthetized state was maintained with continuous 2% isoflurane delivery by a mask. The body temperature was maintained at 37.0 ± 0.3 °C during surgery via a temperature-regulated heating pad. A median incision was made on the neck to separate the right common carotid artery (CCA), right internal carotid artery (ICA), and right external carotid artery (ECA). After the ECA was ligated, a silicon-coated monofilament (diameter: 0.18 ± 0.01 mm, Guangzhou Jialing Co., Ltd, China) was inserted from the right ECA, through the bifurcation of CCA, and into the intracranial segment of ICA (10 ± 1 mm away from the carotid bifurcation) to block blood flow at the middle cerebral artery (MCA) for 45 min. Then, the monofilament was withdrawn to allow reperfusion. Sham-operated animals underwent the same anesthesia and surgical procedures except that the filament was not inserted into ICA. Local cerebral blood flow was monitored by a laser-Doppler blood flowmeter (Periflux 5010, Perimed, Jarfalla, Sweden) to ensure local cerebral blood flow was reduced by 80% of the baseline level. Neurobehavioral evaluation Neurological tests were performed 24 hours after reperfusion to assess behavioral impairments. Behavioral performance was scored according to the 6-point scoring system that monitored appetite, activity, and neurological defects19. Stereotactic injection of adeno-associated virus AAV2/9-Syn-ZsGreen, AAV2/9-Syn-m-Cend1-3xflag-ZsGreen, and AAV2/9-Syn-m-Cend1 mut-3xflag-ZsGreen viruses were purchased from Hanheng Biotechnology Co., Ltd (Shanghai, China). Viruses were stereotactically injected into the striatum (AP + 0.6 mm; ML + 2.0 mm; DV − 3.5 mm). On the 21st day after injection, all mice injected with virus were modeled by MCAO/R. 2, 3, 5-triphenyl tetrazolium chloride staining and infarct volume assessment The procedures used were as described previously. After 1 to 3 days passed since undergoing MCAO/R surgery, the mice were euthanized, and their brains were cut into six 1 mm-thick coronal slices. Sections were stained with 1% 2, 3, 5-triphenyl tetrazolium chloride (TTC) (Sigma-Aldrich, St. Louis, MO, USA) for 15 min at 37 °C, and fixed in 4% paraformaldehyde (PFA) overnight. The images were taken by a digital camera, and the infarct volumes were blindly analyzed with AlphaEaseFC software (Alpha Innotech, USA). Infarct sizes were expressed as percentages of the contralateral structures. Quantitative RT-PCR The specific protocol used has been described previously20. Total RNA was extracted from the brain tissues. The RNA was reverse transcribed into complementary DNA (cDNA) by the commercially-available kits (ABScript III RT Master Mix for qPCR, RK20428, ABclonal Technology Co., Ltd.). RT-PCR was conducted with 2× Universal SYBR Green Fast qPCR Mix (RK21203, ABclonal Technology Co., Ltd.) on the 7500 Real-Time PCR system (Applied Biosystem, USA). Primer sequences are listed as follows: Cend1-F: ACCAGCCAAGGCAGATCCT; Cend1-R: GGTCAAGTTCTCACAAGGCCA; β-actin-F: GTGACGTTGACATCCGTAAAGA; β-actin-R: GCCGGACTCATCGTACTCC. Housekeeping gene expression of β-actin was used for normalization. Relative expression was determined by the 2 −ΔΔCT method21. Western blot analysis Western blot analysis was performed as described previously22. Brain tissues or cultured cells were lysed in RIPA buffer (FD008, Fude Biological Technology) for conventional protein detection or in Dimer-Lysis buffer (25 mM Tris-HCl, 2 mM EDTA, 1% NP-40, 150 mM NaCl) for detection of Cend1 disulfide-linked dimers. Lysates were centrifuged (12,000 r/min, 5 min, 4 °C), and protein concentrations were measured using an Enhanced BCA Protein Assay Kit (P0010S, Beyotime, Shanghai, China). Equal amounts of protein (40 μg/lane) were prepared in the appropriate sample buffer. For conventional protein detection, samples were mixed with SDS buffer and denatured by heating prior to separation by SDS-PAGE. For detection of Cend1 dimers, proteins extracted with Dimer-Lysis buffer were mixed with SDS-free buffer and not heated, and separated under native/non-denaturing PAGE conditions. Proteins were transferred to PVDF membranes, blocked with 5% nonfat milkat room temperature (approximately 25 °C), incubated with primary antibodies overnight at 4 °C, and probed with HRP-conjugated secondary antibodies for 1 h at room temperature (approximately 25 °C). For normalization, housekeeping proteins (GAPDH, β-tubulin, or β-actin) were used as loading controls, with the specific marker selected depending on the experimental context. This ensured comparability within each set of experiments. Although total protein staining is considered a gold standard for normalization, this approach was not applied in the current study. ImageJ (NIH, Bethesda, MD, USA) was used for densitometric analysis of the protein bands. Protein levels were then quantified relative to the loading control. Immunoprecipitation Immunoprecipitation was performed as described previously23. Proteins (500 μg in 500 μl) were pre-incubated with the protein A/G plus-agarose (Santa Cruz, sc-2003; 50 μL per 500 μg protein) for 2 h. After gently centrifuging, the samples were incubated with 5 μg Cend1 antibody, or IgG antibody (as a negative control) for 12 h at 4 °C. After the addition of protein A/G plus-agarose (50 μL per 500 μg protein) for an additional 1 h incubation, the agaroses were gently centrifuged and collected. After washing three times with lysis buffer (150 mM KCl, 10% glycerol, 29 mM Tris, 5 mM MgCl2, 0.5 mL 10% Tween-20, pH 8.0, ddH2O up to 50 mL), the agaroses were eluted by a sample buffer containing Sodium Dodecyl Sulfate. Samples were collected and heated at 95 °C for 15 min for further Western blot analysis. Tissue immunofluorescence staining Mouse brains were perfused with 4% PFA and post-fixed for 24 hours. Tissues were dehydrated in 20% and 30% sucrose solutions sequentially, each for three days, then embedded in OCT and sectioned at 20 μm. Target regions were identified according to a mouse brain atlas. Sections were washed in PBS, permeabilized with 0.3% Triton X-100 for 10 minutes, and blocked in 5% BSA for 1 hour at room temperature. Sections were incubated with primary antibodies overnight at 4 °C, followed by fluorophore-conjugated secondary antibodies for 1 hour at room temperature in the dark. After PBS washes, sections were mounted in glycerol and imaged using a fluorescence microscope. Paraffin sections were baked at 70 °C for 1 hour, deparaffinized in xylene and graded ethanol, and subjected to citrate-based antigen retrieval before antibody staining. Cell immunofluorescence staining Cells were seeded on coverslips, optionally coated with poly-L-lysine. After treatment, cells were fixed with 4% PFA for 30 minutes, washed with PBS, permeabilized with 0.3% Triton X-100 for 10 minutes, and blocked in 5% BSA for 1 hour. Primary antibodies were applied overnight at 4 °C, followed by secondary antibodies for 1 hour at room temperature in the dark. Coverslips were mounted in glycerol and images captured with a fluorescence microscope. Cell fixation and in Cell Western assay Cell fixation and in Cell Western (ICW) assay were performed as described previously24. Treated N2a cells were fixed in 4% paraformaldehyde for 20 min at room temperature. Cells were permeabilized by washing them 5 times with 0.1% Triton X-100 in PBS. Non-specific sites were blocked with 5% BSA in PBS for 2 h at room temperature. Then the sample was incubated with primary antibody overnight at 4 °C. After incubation, the primary antibody solution was removed, and the samples were washed five times with 0.1% Tween-20 in PBS. Then the samples were probed with HRP-conjugated secondary antibodies for 1 h. The secondary antibody solution was washed 5 times with 0.1% Tween-20 in PBS. Finally, images were acquired with an Odyssey CLx Imager Studio 3.1 (Gene Company Limited, Nanjing). Oxygen-glucose deprivation/reperfusion in primary neurons Primary cortical neurons were subjected to oxygen-glucose deprivation/reperfusion (OGD/R) to mimic ischemia/reperfusion injury in vitro. Briefly, neurons were incubated in glucose-free medium and placed in a hypoxic chamber (1% O₂, 5% CO₂, 94% N₂) for 2 h to induce OGD, followed by reperfusion with normal culture medium under normoxic conditions for the indicated times. RNA sequencing and data analysis Total RNA from mouse brain tissues was sequenced on an Illumina HiSeq™ platform with 150 bp paired-end reads. Raw reads were quality-controlled and trimmed using FastQC and Trimmomatic. Clean reads were aligned to the mouse reference genome (GRCm38) using HISAT2. Gene expression quantification and differential expression analysis were performed with StringTie and DESeq2. Differentially expressed genes (DEGs) were defined as those with an absolute log₂ fold change (|log₂FC | ) > 1 and p-value ≤ 0.05. When the number of DEGs identified under these criteria was limited, a P-value ≤ 0.05 was used instead of p-value. Mitochondrial isolation The Mitochondrial Isolation Kit (SM0020, Solarbio, Beijing, China) was utilized to isolate mitochondria according to the manufacturer’s instructions, and the separation was based on differential centrifugation. Isolated mitochondria were directly used for relevant experimental analysis. The purity of the isolated mitochondria was considered high, based on the manufacturer’s instructions and previous reports, with enrichment of mitochondrial markers and minimal cytosolic contamination25. The isolated mitochondria are assumed to retain functional integrity for the intended assays. Mitochondrial membrane potential assay The mitochondrial membrane potential (ΔΨm) was assessed using the Enhanced Mitochondrial Membrane Potential Assay Kit (JC-1) (Beyotime, #C2003). Briefly, after treatment, 293 T cells were collected and resuspended in culture medium. Cells were incubated with JC-1 staining working solution (prepared by diluting JC-1 (200X) 1:200 in JC-1 staining buffer) at 37 °C for 20 min in the dark. After incubation, cells were washed twice with JC-1 staining buffer and resuspended in the same buffer for flow cytometric analysis. The fluorescence of JC-1 monomers (green; excitation/emission: 514/529 nm) and aggregates (red; excitation/emission: 585/590 nm) was detected using a flow cytometer (BD FACSCelestar). ΔΨm was assessed by the percentage of JC-1 monomers (green fluorescence), with an increase in green monomer percentage indicating mitochondrial depolarization. Cells treated with 10 µM CCCP for 20 min served as a positive control. Mitochondrial Permeability Transition Pore opening assay Mitochondrial Permeability Transition Pore (mPTP) opening was evaluated using the Mitochondrial Permeability Transition Pore Assay Kit (Beyotime, #C2009) based on the calcein–cobalt quenching method. After treatment, 293 T cells were collected and incubated with Calcein AM staining working solution (containing 1X Calcein AM and 1X CoCl₂) at 37 °C for 30 min in the dark. Cells were washed twice with assay buffer and further incubated in pre-warmed culture medium (without serum) for 30 min at 37 °C to ensure complete hydrolysis of Calcein AM. The cells were then washed, resuspended in assay buffer, and analyzed using a flow cytometer (excitation: 488 nm; emission: 525/30 nm FITC channel, BD FACSCelestar). A decrease in calcein fluorescence indicates increased mPTP opening. Ionomycin (0.5 μM) was used as a positive control. Data were analyzed using flow cytometry software (FlowJo 10.9). ATP content assay ATP levels in 293T cells and mouse brain tissues were determined using the ATP Assay Kit (Beyotime, #S0026). Cells or homogenized tissues were lysed in ATP detection lysis buffer on ice. Lysates were centrifuged at 12,000 × g and 4 °C for 5 min, and the supernatant was collected. ATP concentrations were measured by mixing 20 µl of supernatant with 100 µl of ATP detection working solution (prepared by diluting ATP detection reagent 1:9 with ATP detection reagent diluent) in a luminometer tube. Chemiluminescence was recorded using a luminometer after a 2-second delay. A standard curve was generated using known ATP concentrations for quantification. ATP levels were normalized to total protein concentration determined by BCA assay (Beyotime, P0010S). Measurement of mitochondrial complex I and V Activities Activities of mitochondrial complex I and V in 293 T cells were measured using the Cell Mitochondrial Complex I Activity Assay Kit (Elabscience, #E-BC-K834-M) and Complex V Activity Assay Kit (Elabscience, #E-BC-K838-M), respectively, according to the manufacturer’s instructions. Briefly, cells were collected and lysed in extraction buffer containing protease inhibitors. Lysates were sonicated on ice (200 W, 5 s on/10 s off, 15 cycles) and centrifuged at 10,000 × g for 3 min at 4 °C. The supernatant was used for enzymatic activity assays. Complex I and V activities were determined by monitoring NADH oxidation at 340 nm using a microplate reader (Molecular Devices SpectraMax M3). Total protein concentration was measured by BCA assay for normalization. Rotarod test The Rotarod test was employed to measure the motor coordination of mice after cerebral ischemia treatment. The diameter of the rotarod spindle was 3 cm. Mice were placed on an accelerated rotarod. The instrument was then accelerated from 8 to 40 rpm in 60 s and 40 rpm was maintained for a maximum of 300 s. The latency to fall (in seconds) was recorded before test mice were trained to learn to run. Grip strength test In order to measure the grasping strength of the forepaws, the grip strength test was performed on days 1, 3, 5, and 7 after MCAO/R surgery. A digital force gauge instrument (YLS-13A Instrutherm, Shanghai, China) was used. The forepaws were put on the metal bar attached to a strain gauge. Then the animal was gently pulled by the tail until it released the bar. The data collected from the three trials were recorded in grams, and the mean value for each animal was calculated. Foot fault(s) test The placement dysfunction of the forelimbs was tested using the foot fault(s) test. We performed behavioral tests on days 1, 3, 5, and 7 after MCAO/R surgery. Mice were put on an elevated grid surface and placed their paws on the wire while moving along the grid. Foot fault represented paws falling between grid bars. The number of foot fault(s) on both sides was recorded for 2 min and the difference of foot faults between each side was used for statistical analysis. Statistical analysis All data were analyzed using the GraphPad Prism version 9.0 and presented as mean ± SEM. P < 0.05 was considered as a statistical significance. Two-tailed unpaired Student’s t-test was used to compare the differences between the two groups. Two-way ANOVA with a post hoc test was used for differences among groups. The experiments were performed independently on three or more samples, which refer to individual animals in in vivo experiments and independent cultures in in vitro experiments. Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article. Results Cend1 protein levels increased in the brain after ischemic injury Because mitochondrial functions are a determining factor for cell fate after cerebral ischemia, we first examined Cend1 protein levels in mitochondrial and cytosolic fractions isolated from mouse striatal tissue at 24 h after MCAO/R using a mitochondrial separation kit. Western blot analysis showed that Cend1 was more abundant in the mitochondrial fraction than in the cytosolic fraction, and its expression in mitochondria was significantly increased compared with the sham group (Fig. 1A, B). Although potential contamination from other cellular compartments cannot be entirely excluded with this approach, these data suggest that Cend1 is enriched in mitochondrial preparations and upregulated after ischemia-reperfusion. Based on this observation, we next assessed the temporal profile of Cend1 expression in ischemic brain tissue. After MCAO/R, Cend1 protein levels in the ischemic hemisphere increased significantly at 24 h, peaked at 72 h, and returned to baseline by 7 d (Fig. 1C, D). In contrast, after reanalysis of the original full-size blot images with uniform background correction and housekeeping normalization, Cend1 expression remained unchanged in the contralateral non-ischemic hemisphere (Fig. 1E, F). Similarly, Cend1 protein levels were also significantly increased at 24 h and peaked at 72 h in cultured primary neurons after OGD/R (Fig. 1G–H). Double-immunofluorescent staining confirmed the ischemic insult-induced increases in Cend1 protein levels in primary neurons after 24 h of OGD/R (Fig. 1I–J). Taken together, these results demonstrate that Cend1 protein levels increased after ischemia insults.Fig. 1Cend1 levels significantly increased after ischemia-reperfusion injury.A At 24 h after MCAO/R, the striatum tissues of C57BL/6J mice were collected and mitochondria in brain tissues were extracted by mitochondrial separation kit. Protein levels of Cend1 in mitochondria was examined by western blot analysis. B The quantitative analysis of Cend1 protein levels was performed. N = 3. C At different time points after MCAO/R, the brain tissues in the ischemic core were collected. Cend1 protein was examined by Western blot analysis. D The quantitative analysis of Cend1 protein levels was determined. N = 5. E At different time points after MCAO/R, brain tissues in the same regions on the ischemic contralateral side were collected. Cend1 protein levels were examined by western blot analysis. Densitometric analysis of six independent samples showed no significant difference compared with controls. F The quantification of Cend1 protein levels was performed. N = 5. G After primary neurons were cultured for 7 d, the cultured neurons were subjected to OGD/R. At different time points after re-oxygenation, the neurons were collected. Cend1 protein levels were detected by western blot analysis. H The quantification of Cend1 protein levels was also shown. N = 3. I After primary neurons were cultured for 7 d, the cultured neurons were subjected to OGD/R. At 24 h after re-oxygenation, double-immunofluorescence analysis was performed with Cend1 antibody (green), and the neuronal marker NeuN (red). The nuclei were fluorescently labeled with DAPI (blue). Scale bar: 50 μm. J Quantitative analysis of the relative mean fluorescence intensity of Cend1 in neurons was shown. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ns, not significant. Cend1 levels significantly increased after ischemia-reperfusion injury. A At 24 h after MCAO/R, the striatum tissues of C57BL/6J mice were collected and mitochondria in brain tissues were extracted by mitochondrial separation kit. Protein levels of Cend1 in mitochondria was examined by western blot analysis. B The quantitative analysis of Cend1 protein levels was performed. N = 3. C At different time points after MCAO/R, the brain tissues in the ischemic core were collected. Cend1 protein was examined by Western blot analysis. D The quantitative analysis of Cend1 protein levels was determined. N = 5. E At different time points after MCAO/R, brain tissues in the same regions on the ischemic contralateral side were collected. Cend1 protein levels were examined by western blot analysis. Densitometric analysis of six independent samples showed no significant difference compared with controls. F The quantification of Cend1 protein levels was performed. N = 5. G After primary neurons were cultured for 7 d, the cultured neurons were subjected to OGD/R. At different time points after re-oxygenation, the neurons were collected. Cend1 protein levels were detected by western blot analysis. H The quantification of Cend1 protein levels was also shown. N = 3. I After primary neurons were cultured for 7 d, the cultured neurons were subjected to OGD/R. At 24 h after re-oxygenation, double-immunofluorescence analysis was performed with Cend1 antibody (green), and the neuronal marker NeuN (red). The nuclei were fluorescently labeled with DAPI (blue). Scale bar: 50 μm. J Quantitative analysis of the relative mean fluorescence intensity of Cend1 in neurons was shown. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ns, not significant. Cend1 deficiency aggravated cerebral ischemia/reperfusion injury in mice To explore whether Cend1 plays a critical role in cerebral ischemic injury, Cend1 knockout (KO) mice were generated by deleting exon 2 of the Cend1 gene using CRISPR/Cas9 technology (Fig. S1A). Exon 2 contains the translation initiation site, and its deletion introduces a frameshift and premature stop codon, thereby ensuring a null allele and complete loss of functional Cend1 protein. Cend1 KO was confirmed by Sanger sequencing, PCR, and western blotting (Fig. S1B–D). Cend1 deficiency had no effects on the body weight and shape of mice (Fig. S1E, F). Wild-type (WT) mice and Cend1 KO mice were subjected to MCAO for 45 min and were re-perfused for 24 h (Fig. 2A). Neurological function was assessed using a 6-point scoring system, where higher scores indicate more severe deficits. At 24 h after MCAO/R, Cend1 KO mice displayed markedly higher neurological deficit scores compared with WT mice (Fig. 2B). Consistently, TTC staining revealed significantly larger infarct volumes in Cend1 KO mice (Fig. 2C–D), indicating that Cend1 deficiency exacerbates both functional impairment and cerebral infarction following ischemic injury. Finally, to further determine the role of Cend1 in ischemic stroke, the sensory and motor deficits in Cend1 KO and WT mice were evaluated by the rotarod test, grip strength test, and foot-fault test. Rotarod test showed that on days 3, 5, and 7 after MCAO/R, the times on the rotarod in Cend1 KO mice were shorter than that in WT mice (Fig. 2E). In the grip strength test, Cend1 KO mice had weaker forelimb strength than WT mice at days 3, 5 and 7 after MCAO/R (Fig. 2F). The foot-fault test showed that the number of foot-fault steps in Cend1 KO mice was higher than that in WT mice at days 3 and 5 after MCAO/R (Fig. 2G). However, there was no significant change in all behavioral tests between Cend1 KO and WT mice that did not undergo the MCAO/R. Although the effects of Cend1 KO on post-ischemic behavioral outcomes were moderate, they were consistently significant across multiple assessments, supporting a meaningful role for Cend1 in pathways activated after cerebral ischemia/reperfusion injury.Fig. 2Cend1 deficiency aggravated the damage induced by brain ischemia.A An experimental flowchart of mouse modeling and subsequent analysis was shown. B At 24 h after MCAO/R, a 6-point scoring system was used to evaluate the neurological deficits in mice. N = 5. C 2, 3, 5-triphenyltetrazolium chloride (TTC) staining of coronal brain sections was performed at 24 h after MCAO/R. Representative graphs from WT (Cend1+/+) mice and Cend1 KO (Cend1-/-) mice were shown. D The infract volume was quantified and expressed as the percentage of the contralateral hemispheric volume. N = 5. E In the rotarod test, the time of falling from the rotating rod in different groups of mice was recorded from day 1 to day 7 after MCAO/R. N = 10. F In the grip strength test, the strength of forelimbs of mice in different groups was examined daily. N = 10. G In the foot fault test, the mice in different groups were placed on the iron grid with a high frame. The times of left foot and right foot falling from the grid were recorded. The foot fault times were calculated by left side -right side. N = 10. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01. Cend1 deficiency aggravated the damage induced by brain ischemia. A An experimental flowchart of mouse modeling and subsequent analysis was shown. B At 24 h after MCAO/R, a 6-point scoring system was used to evaluate the neurological deficits in mice. N = 5. C 2, 3, 5-triphenyltetrazolium chloride (TTC) staining of coronal brain sections was performed at 24 h after MCAO/R. Representative graphs from WT (Cend1+/+) mice and Cend1 KO (Cend1-/-) mice were shown. D The infract volume was quantified and expressed as the percentage of the contralateral hemispheric volume. N = 5. E In the rotarod test, the time of falling from the rotating rod in different groups of mice was recorded from day 1 to day 7 after MCAO/R. N = 10. F In the grip strength test, the strength of forelimbs of mice in different groups was examined daily. N = 10. G In the foot fault test, the mice in different groups were placed on the iron grid with a high frame. The times of left foot and right foot falling from the grid were recorded. The foot fault times were calculated by left side -right side. N = 10. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01. Cend1 regulated cellular ATP production through Cend1 dimers High-throughput RNA sequencing was performed on Cend1 KO and WT mouse brains to identify differentially expressed genes (DEGs) associated with Cend1 deficiency. The data showed that there were 83 differentially expressed genes (DEGs), as shown in Fig. S2A. Among them, 73 genes were significantly upregulated and 10 genes were significantly downregulated, with |log₂FC | > 1 and p-value ≤ 0.05 (Fig. S2A). The enrichment analysis of DEGs revealed that they were markedly enriched in mitochondrial organization and regulation of neuron apoptotic process (Fig. S2B). Interestingly, a Protein–Protein Interaction network was constructed, and key MCODE components were extracted; the most significant component was the ATP metabolic process (Fig. S2C, D). The results indicated that Cend1 KO may worsen brain injury by impaired mitochondrial functions and cellular ATP production. To verify whether Cend1 KO worsened brain injury by impairing mitochondrial functions and cellular ATP production, total ATP levels in brain tissues of Cend1 KO and WT mice were measured using a commercial ATP detection kit. ATP levels were normalized to protein concentration in each sample, and the results are expressed as relative ATP content compared with the mean value of WT mice. Results showed that total ATP production significantly decreased in Cend1 KO mice compared with WT mice (Fig. 3A), indicating that Cend1 may regulate mitochondrial functions and cellular ATP production. To assess the oligomeric state of Cend1, brain lysates were analyzed by SDS-PAGE and native PAGE without SDS. Interestingly, two bands at 22 kDa and 44 kDa were observed in native PAGE but were absent in Cend1 KO mice (Fig. 3B), suggesting that Cend1 may form dimers under physiological or pathological conditions. To understand the role of Cend1 dimerization, we examined its formation under physiological and pathological conditions. While many proteins, including some mitochondrial proteins such as Bcl-2 family members, are known to form dimers, the precise functional implications of Cend1 dimerization remain only partially addressed. In OGD/R-treated primary neurons, levels of Cend1 monomers and dimers were significantly increased at 2 d and peaked at 4 d after OGD/R (Fig. 3C, D).Fig. 3Glycine 130 and 141 sites in the transmembrane domain were critical for the dimerization of Cend1.A Brain tissues from WT mice and Cend1 KO mice were collected at 24 h after MCAO/R. The ATP content in each sample was measured using an ATP detection kit and normalized to protein concentration. Relative ATP levels are presented as fold changes compared with the mean of WT mice, which was set as 1. N = 5. B Brain tissues from WT mice and Cend1 KO mice were collected and lysed in lysis buffers with or without SDS. A~22 kDa band corresponding to the Cend1 monomer was detected under SDS conditions, whereas a~44 kDa band corresponding to the dimer was observed under non-SDS conditions in WT but not in KO tissues. C Primary neurons were cultured for 7 days, and then were subjected to OGD/R. At different time points after re-oxygenation, the neurons were collected and lysed in lysis buffer without SDS. Monomers (22 kDa) and dimers (44 kDa) of Cend1 protein were examined by western blot analysis under non-SDS conditions. A representative graph was shown. D Monomer and dimer levels of Cend1 protein at different time points were performed. N = 3. E A schematic diagram showed different plasmids that encoded WT, proline-substitutions (G130P and G141P), or transmembrane domain deletion (▲TM) Cend1 protein. A red P indicated the proline-substitution in the GXXXA motifs. F After HEK293 cells were co-transfected with the different plasmids for 48 h, cell lysates were collected for western blot analysis under non-SDS conditions to detect the monomers and dimers of Cend1 protein. G HEK293T cells were transfected with empty vector plasmid, WT Cend1 plasmid, or mutant Cend1 plasmid (G130P) for 48 h. Transfected HEK293T cells were harvested, and the ATP content in HEK293T cells were determined. G130P was selected as a representative mutant; other mutants disrupting the transmembrane domain or GXXXA motif showed similar effects on dimerization and protein stability. N = 6. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ns, not significant. Glycine 130 and 141 sites in the transmembrane domain were critical for the dimerization of Cend1. A Brain tissues from WT mice and Cend1 KO mice were collected at 24 h after MCAO/R. The ATP content in each sample was measured using an ATP detection kit and normalized to protein concentration. Relative ATP levels are presented as fold changes compared with the mean of WT mice, which was set as 1. N = 5. B Brain tissues from WT mice and Cend1 KO mice were collected and lysed in lysis buffers with or without SDS. A~22 kDa band corresponding to the Cend1 monomer was detected under SDS conditions, whereas a~44 kDa band corresponding to the dimer was observed under non-SDS conditions in WT but not in KO tissues. C Primary neurons were cultured for 7 days, and then were subjected to OGD/R. At different time points after re-oxygenation, the neurons were collected and lysed in lysis buffer without SDS. Monomers (22 kDa) and dimers (44 kDa) of Cend1 protein were examined by western blot analysis under non-SDS conditions. A representative graph was shown. D Monomer and dimer levels of Cend1 protein at different time points were performed. N = 3. E A schematic diagram showed different plasmids that encoded WT, proline-substitutions (G130P and G141P), or transmembrane domain deletion (▲TM) Cend1 protein. A red P indicated the proline-substitution in the GXXXA motifs. F After HEK293 cells were co-transfected with the different plasmids for 48 h, cell lysates were collected for western blot analysis under non-SDS conditions to detect the monomers and dimers of Cend1 protein. G HEK293T cells were transfected with empty vector plasmid, WT Cend1 plasmid, or mutant Cend1 plasmid (G130P) for 48 h. Transfected HEK293T cells were harvested, and the ATP content in HEK293T cells were determined. G130P was selected as a representative mutant; other mutants disrupting the transmembrane domain or GXXXA motif showed similar effects on dimerization and protein stability. N = 6. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ns, not significant. By comparing the sequence of Cend1 protein in multiple organisms, the transmembrane domain of Cend1 was found to be highly conserved in humans, mice, and rats, containing two typical GXXXA motifs. Notably, similar GXXXA motifs were also identified in avian species such as chicken and canary, although their positions within the transmembrane region were slightly shifted, suggesting that this structural feature is evolutionarily conserved (Fig. S3A). To investigate the involvement of the GXXXA motif in the dimerization of Cend1, plasmids encoding wild-type (WT) and mutant forms of Cend1 were constructed (Fig. S3A; results shown in Fig. 3E). The mutant forms included: G130P and G141P, in which Glycine 130 and Glycine 141 were substituted with a proline, respectively, and ▴TM, in which residues 125-145 were deleted. These plasmids were transfected in N2a cells, a neuronal cell line with high transfection efficiency, to analyze the expression and molecular forms (monomers and dimers) of exogenous Cend1. Our results showed that ▴TM Cend1 plasmids-transfected cells almost had no Cend1 dimer bands, and G130P/G141P Cend1-transfected cells had a slight dimer band. On the contrary, ▴TM Cend1 plasmids-transfected cells had a thick monomer band compared with WT Cend1 plasmid-transfected cells (Fig. 3F). G130P was selected as a representative mutant because its effect on dimerization and protein stability was similar to other mutants (G141, G130P/G141P, ▴TM, Fig. 3F). HEK293T cells were chosen for these assays due to their high transfection efficiency and suitability for protein expression and mutational analyses, providing a robust system to evaluate Cend1 dimerization. These findings indicate that the transmembrane domain and the GXXXA motif are crucial for the dimerization of Cend1. More importantly, ATP production significantly decreased in G130P-transfected cells compared with WT plasmid-transfected cells (Fig. 3G). Therefore, our findings indicate that Cend1 can form dimers, which may be involved in ATP production and mitochondrial-related processes. Cend1 mutants failed to provide neuroprotection on cerebral ischemic injury To investigate the role of Cend1 dimers in the context of cerebral ischemia/reperfusion (I/R) injury, viruses carrying WT Cend1, Cend1-G130P, or a blank vector (NC) were injected into the striatum of C57BL/6 J wild-type mice. We used WT mice for this experiment - providing a normal physiological context devoid of the compensatory adaptations that complicate interpretation in the Cend1 KO model. (Fig. S4A). Injection sites and virus-infected areas were shown in Fig. S4B. Cend1 mRNA expression was detected by RT-PCR as shown in Fig. 4A. The infection with WT-Cend1 and CendG130P viruses resulted in an increase of Cend1 mRNA levels compared to the control (Fig. 4A). Western blotting analysis using anti-FLAG antibody showed a specific exogenous Cend1 band at approximately 25 kDa in WT Cend1 virus-treated mice, but not in NC virus- or Cend1-G130P virus-treated mice (Fig. 4B). Anti-GFP antibody was used to verify the expression of viral vectors. Furthermore, the viruses were injected into the striatum of C57BL/6 J mice. TTC staining and behavioral tests were performed after cerebral ischemia/reperfusion injury as shown in Fig. 4C. Neurological scores significantly decreased in WT Cend1 virus-treated mice, but not in Cend1-G130P virus-treated mice and NC virus-treated mice (Fig. 4D). Similarly, infarct volume markedly reduced in WT Cend1 virus-treated mice, but not in Cend1-G130P virus-treated mice (Fig. 4E, F). In addition, WT Cend1 virus treatment alleviated neurological deficits in the rotarod test (Fig. 4G), grip strength test (Fig. 4H), and foot-fault test (Fig. 4I), but Cend1-G130P virus treatment did not. The Rotarod test showed that on days 3, 5, and 7 after MCAO/R, the times on the rotarod in the WT Cend1 virus treatment group were longer than that in the NC virus treatment group (Fig. 4G). The grip strength test showed that WT Cend1 virus treatment mice showed stronger forelimb strength than NC virus treatment mice at days 3, 5, and 7 after MCAO/R (Fig. 4H). The foot-fault test showed that the number of foot-fault steps in the WT Cend1 virus treatment mice group was less than the NC virus treatment mice group at days 1, 3, and 7 after MCAO/R (Fig. 4I). These findings demonstrate that exogenous WT Cend1 improved cerebral ischemia/reperfusion injury but not mutant G130P Cend1.Fig. 4G130P mutant abolished the protection of Cend1 protein against cerebral ischemia reperfusion injury.A Packaged virus control (AAV2/9 negative control, short for NC), Cend1-overexpression viruses, and Cend1-G130P viruses were injected into the striatum of C57BL/6 J mice by a stereotactic method. At 21 d after virus injection, the striatum was collected for RNA extraction. Cend1 mRNA was examined by quantitative RT-PCR analysis. N = 5. B At 21 days after virus injection, Western blot analysis was performed. Exogenous Cend1 expression was detected with anti-FLAG antibody, and viral transduction efficiency was verified with anti-GFP antibody. A Cend1-specific band (~25 kDa) was observed in the WT Cend1 virus group, but not in NC virus or Cend1-G130P virus groups. C A diagram showed the workflow for mice injected with different viruses. D At 24 h after MCAO/R, a 6-point scoring system was used to evaluate the neurological deficits in three groups of mice. E Representative TTC staining of coronal brain sections after MCAO/R was shown in three groups. F The infarct volume was quantified in three groups and expressed as the percentage of the contralateral hemispheric volume. N = 6. G In the rotarod test, the time of falling from the rotating rod in three groups was recorded from day 1 to day 7 after MCAO/R. N = 10. H In the grip strength test, the strength of forelimbs of mice in different groups was examined daily. N = 10. I In the foot fault test, the mice in different groups were placed on the iron grid with a high frame. The times of left foot and right foot falling from the grid were recorded. The foot fault times were calculated by left side -right side. N = 10. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ns, not significant. G130P mutant abolished the protection of Cend1 protein against cerebral ischemia reperfusion injury. A Packaged virus control (AAV2/9 negative control, short for NC), Cend1-overexpression viruses, and Cend1-G130P viruses were injected into the striatum of C57BL/6 J mice by a stereotactic method. At 21 d after virus injection, the striatum was collected for RNA extraction. Cend1 mRNA was examined by quantitative RT-PCR analysis. N = 5. B At 21 days after virus injection, Western blot analysis was performed. Exogenous Cend1 expression was detected with anti-FLAG antibody, and viral transduction efficiency was verified with anti-GFP antibody. A Cend1-specific band (~25 kDa) was observed in the WT Cend1 virus group, but not in NC virus or Cend1-G130P virus groups. C A diagram showed the workflow for mice injected with different viruses. D At 24 h after MCAO/R, a 6-point scoring system was used to evaluate the neurological deficits in three groups of mice. E Representative TTC staining of coronal brain sections after MCAO/R was shown in three groups. F The infarct volume was quantified in three groups and expressed as the percentage of the contralateral hemispheric volume. N = 6. G In the rotarod test, the time of falling from the rotating rod in three groups was recorded from day 1 to day 7 after MCAO/R. N = 10. H In the grip strength test, the strength of forelimbs of mice in different groups was examined daily. N = 10. I In the foot fault test, the mice in different groups were placed on the iron grid with a high frame. The times of left foot and right foot falling from the grid were recorded. The foot fault times were calculated by left side -right side. N = 10. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ns, not significant. These findings prompted us to investigate whether Cend1 mitigates ischemia/reperfusion-induced injury by regulating mitochondrial function. To this end, 293T cells were transfected with either wild-type Cend1 or the mutant Cend1-G130P and subjected to an in vitro OGD/R model. As shown in Fig. 5A, B, JC-1 staining revealed a significant increase in the proportion of JC-1 monomers following OGD, indicating a loss of mitochondrial membrane potential (ΔΨm). Overexpression of wild-type Cend1 effectively reversed this change, whereas the Cend1-G130P mutant failed to confer protection. Similarly, calcein–cobalt fluorescence measurements demonstrated a marked decrease in fluorescence intensity after OGD/R, reflecting increased mitochondrial permeability transition pore (mPTP) opening; this effect was rescued by wild-type Cend1 but not by Cend1-G130P (Fig. 5C, D). Moreover, OGD/R induced a significant reduction in NADH–CoQ reductase (complex I) activity and F₁F₀-ATP synthase (complex V) activity, both of which were restored by wild-type Cend1 overexpression but remained impaired with Cend1-G130P (Fig. 5E, F). Additionally, wild-type Cend1 maintained higher intracellular ATP levels after OGD/R, whereas the mutant form did not (Fig. 5G). Collectively, these results indicate that Cend1 may contribute to preserving mitochondrial structural integrity and energy metabolism under ischemic stress.Fig. 5Cend1 mutants failed to provide neuroprotection against ischemic injury in 293 T cells.293 T cells were transfected with empty vector, wild-type Cend1, or the Cend1-G130P mutant for 48 h, followed by oxygen–glucose deprivation/reoxygenation (OGD/R) treatment. Cells were collected 24 h after reoxygenation for subsequent analyses. A Representative flow cytometric analysis of JC-1 staining showing the proportion of monomers and aggregates. B Quantification of JC-1 monomer proportion. N = 3. C Representative flow cytometric analysis of calcein–cobalt staining to assess mPTP opening. D Quantification of calcein fluorescence intensity. N = 3. E Relative NADH–CoQ reductase (complex I) activity measured using a mitochondrial complex I assay kit. N = 3. F Relative F₁F₀-ATP synthase (complex V) activity measured using a mitochondrial complex V assay kit. N = 3. G Intracellular ATP levels measured by ATP assay kit and normalized to protein content. N = 3. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ns, not significant. Cend1 mutants failed to provide neuroprotection against ischemic injury in 293 T cells. 293 T cells were transfected with empty vector, wild-type Cend1, or the Cend1-G130P mutant for 48 h, followed by oxygen–glucose deprivation/reoxygenation (OGD/R) treatment. Cells were collected 24 h after reoxygenation for subsequent analyses. A Representative flow cytometric analysis of JC-1 staining showing the proportion of monomers and aggregates. B Quantification of JC-1 monomer proportion. N = 3. C Representative flow cytometric analysis of calcein–cobalt staining to assess mPTP opening. D Quantification of calcein fluorescence intensity. N = 3. E Relative NADH–CoQ reductase (complex I) activity measured using a mitochondrial complex I assay kit. N = 3. F Relative F₁F₀-ATP synthase (complex V) activity measured using a mitochondrial complex V assay kit. N = 3. G Intracellular ATP levels measured by ATP assay kit and normalized to protein content. N = 3. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ns, not significant. Disruption of Cend1 dimers promoted the degradation of Cend1 To gain a better understanding of why mutant Cend1 abolished the neuroprotection by WT Cend1 on cerebral ischemic injury, Cend1 expression was examined after the injection of different viruses into the striatum of Cend1 KO mice. western blot results showed that exogenous Cend1 expression was only detected in WT Cend1 virus-injected mice, but not in mutant Cend1 virus-injected mice (Fig. 6A–B). Given the inconsistency between transcription and protein levels, it was speculated that mutant Cend1 may decrease protein stability and cause degradation of the Cend1 protein. To verify this, 293 T cells were transfected with WT Cend1 or Cend1-G130P plasmid, and then treated with cycloheximide to block protein synthesis. The slope of the Cend1-G130P Cend1 degradation curve was much steeper than that in the WT Cend1 degradation curve (Fig. 6C–D). In summary, mutant Cend1 accelerated the degradation of the Cend1 protein.Fig. 6Monomeric Cend1 mutants were prone to degrade.A Packaged virus control (AAV2/9 negative control, NC), Cend1-overexpression (Over-Cend1) viruses, and Cend1-G130P viruses were injected into the striatum of Cend1 KO mice by a stereotactic method. At 21 d after Over-Cend1, Cend1-G130 or NC virus injection in Cend1 KO mice, the brain tissues of three groups of mice were collected. Monomers and dimers of Cend1 protein was detected by western blot analysis under non-SDS conditions. B Monomers and dimers of Cend1 protein were quantified. N = 3. C After HEK293 cells were co-transfected with Cend1 plasmid or Cend1-G130P plasmid for 24 h, the cells were treated with CHX (30 μg/ml) for 0, 1, 2, 4, 8, and 12 h. Cell lysates were collected for western blot analysis under non-SDS conditions to detect monomers and dimers of Cend1 protein. D The quantitative analysis of Cend1 monomer and dimer protein levels was performed. N = 3. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01. Monomeric Cend1 mutants were prone to degrade. A Packaged virus control (AAV2/9 negative control, NC), Cend1-overexpression (Over-Cend1) viruses, and Cend1-G130P viruses were injected into the striatum of Cend1 KO mice by a stereotactic method. At 21 d after Over-Cend1, Cend1-G130 or NC virus injection in Cend1 KO mice, the brain tissues of three groups of mice were collected. Monomers and dimers of Cend1 protein was detected by western blot analysis under non-SDS conditions. B Monomers and dimers of Cend1 protein were quantified. N = 3. C After HEK293 cells were co-transfected with Cend1 plasmid or Cend1-G130P plasmid for 24 h, the cells were treated with CHX (30 μg/ml) for 0, 1, 2, 4, 8, and 12 h. Cell lysates were collected for western blot analysis under non-SDS conditions to detect monomers and dimers of Cend1 protein. D The quantitative analysis of Cend1 monomer and dimer protein levels was performed. N = 3. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01. Cend1 interacted with the mitochondrial protein Atp5f1b after cerebral ischemia/reperfusion injury To explore the underlying mechanisms of Cend1 in regulating mitochondrial functions and ATP production, immunoprecipitation combined with mass spectrometry (IP-MS) was performed to identify Cend1-interacting proteins in mitochondria by using Cend1 antibody and isolated protein lysate from WT and Cend1 KO mouse brain tissues (Fig. 7A). Mass spectrometry data revealed that there were many potential Cend1-interacting proteins that were enriched in different signaling pathways, including mitochondria-related signaling pathways (Fig. 7B). Compared with Cend1 KO samples, there were 69 potential Cend1-interacting proteins in WT mouse results. After comparing the 69 potential Cend1-interacting proteins with the reported mitochondrial database (MitoCarta 3.0), only eight mitochondrial proteins were identified, including ATP synthase β subunit (Atp5f1b, Fig. 7C). Because previous studies have demonstrated that Atp5f1b encodes the catalytic β subunit of ATP synthase, which is responsible for the synthesis of the majority of cellular ATP and has also been proposed as the putative mitochondrial permeability transition pore26, further validation was conducted to assess whether Cend1 dimers form a complex with the ATP synthase β subunit to influence mitochondrial functions. The expression and cellular localization of Atp5f1b proteins were not changed in Cend1 KO mice. (Fig. S5A, B). By co-transfecting 293T cells with Flag-Cend1 and EGFP-Atp5f1b plasmids (Fig. 7D), or EGFP-Cend1 and HA-Atp5f1b plasmids (Fig. 7E), the results showed that ATP synthase β subunit (Atp5f1b) and Cend1 co-immunoprecipitated. Similarly, Atp5f1b was a co-immunoprecipitated protein of Cend1 by using Cend1 antibody to precipitate endogenous Cend1 in brain tissues (Fig. 7F). Furthermore, immunoprecipitation assays in ischemic brain tissues using Cend1 antibodies showed a significant increase in relative Atp5f1b protein compared to sham controls (Fig. 7G). Quantitative analysis confirmed the increase of relative immunoprecipitated Atp5f1b with Cend1 in ischemic conditions (Fig. 7H). These results indicate that ATP synthase β subunit (Atp5f1b) interacts with Cend1, suggesting that Cend1 may influence mitochondrial ATP synthesis and permeability transition pore function through its association with ATP synthase.Fig. 7Cend1 interacted with Atp5f1b after MCAO/R.A A diagram showed the workflow for IP-MS. B The striatum of Cend1 WT mice and Cend1 KO mice were separated to make cell lysates, and then the immunoprecipitation was carried out with Cend1 antibody, and the enriched products obtained by immunoprecipitation were analyzed by IP-MS. Metascape was used to analyze the functional enrichment of all the identified Cend1-interacting proteins. Network of enriched terms: colored by cluster ID, where nodes that share the same cluster ID were typically close to each other. C IP-MS data showed that 69 potential proteins were candidates Cend1-interacting proteins. In order to focus on mitochondrial proteins, VENN analysis was performed on 69 proteins that may interact with Cend1 and they were compared with the known mitochondrial database (MitoCarta 3.0). Eight mitochondrial proteins were identified. D HEK293 cells were transfected with EGFP-Atp5f1b and FLAG or FLAG-Cend1 plasmids for 48 h. Cell lysates were subject to immunoprecipitation assay with anti-FLAG antibody. Immunoprecipitated proteins were subjected to western blot analysis to detect GFP (Atp5f1b) and FLAG (Cend1). E Similarly, HEK293 cells were transfected with EGFP-Cend1 and HA or HA-Atp5f1b plasmids for 48 h. Cell lysates were subject to immunoprecipitation assay with anti-HA antibody. Immunoprecipitated proteins were subjected to western blot analysis to detect GFP (Cend1) and HA (Atp5f1b). F C57BL/6J mouse striatum lysates were subject to immunoprecipitation assay with anti-Cend1 antibody or control IgG. Immunoprecipitated proteins were subjected to western blot analysis to detect Cend1 and Atp5f1b. G At 24 h after MCAO/R, brain tissues from ischemic core in the MCAO/R group and the same region tissues in the sham group were collected. Immunoprecipitation assay was performed by using Cend1 antibody. Cend1 and Atp5f1b was further detected by western blot analysis. H The quantitative analysis of Atp5f1b protein levels was performed in IP group. N = 3. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ns, not significant. Cend1 interacted with Atp5f1b after MCAO/R. A A diagram showed the workflow for IP-MS. B The striatum of Cend1 WT mice and Cend1 KO mice were separated to make cell lysates, and then the immunoprecipitation was carried out with Cend1 antibody, and the enriched products obtained by immunoprecipitation were analyzed by IP-MS. Metascape was used to analyze the functional enrichment of all the identified Cend1-interacting proteins. Network of enriched terms: colored by cluster ID, where nodes that share the same cluster ID were typically close to each other. C IP-MS data showed that 69 potential proteins were candidates Cend1-interacting proteins. In order to focus on mitochondrial proteins, VENN analysis was performed on 69 proteins that may interact with Cend1 and they were compared with the known mitochondrial database (MitoCarta 3.0). Eight mitochondrial proteins were identified. D HEK293 cells were transfected with EGFP-Atp5f1b and FLAG or FLAG-Cend1 plasmids for 48 h. Cell lysates were subject to immunoprecipitation assay with anti-FLAG antibody. Immunoprecipitated proteins were subjected to western blot analysis to detect GFP (Atp5f1b) and FLAG (Cend1). E Similarly, HEK293 cells were transfected with EGFP-Cend1 and HA or HA-Atp5f1b plasmids for 48 h. Cell lysates were subject to immunoprecipitation assay with anti-HA antibody. Immunoprecipitated proteins were subjected to western blot analysis to detect GFP (Cend1) and HA (Atp5f1b). F C57BL/6J mouse striatum lysates were subject to immunoprecipitation assay with anti-Cend1 antibody or control IgG. Immunoprecipitated proteins were subjected to western blot analysis to detect Cend1 and Atp5f1b. G At 24 h after MCAO/R, brain tissues from ischemic core in the MCAO/R group and the same region tissues in the sham group were collected. Immunoprecipitation assay was performed by using Cend1 antibody. Cend1 and Atp5f1b was further detected by western blot analysis. H The quantitative analysis of Atp5f1b protein levels was performed in IP group. N = 3. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ns, not significant. Increasing Cend1 dimers by TNT provided neuroprotection on cerebral ischemia/reperfusion injury Since Cend1 provides neuroprotection against cerebral ischemia injuries, it is possible to identify small molecule compounds that increase cellular Cend1 for stroke treatment. Therefore, a small molecule compound library was screened using a cell-based assay (Fig. S6A). Interestingly, the small molecule compound TNT (Fig. 8A) was found to significantly increase cellular Cend1 protein level (Fig. S6B, C). TNT modestly but significantly increased the Cend1 protein level in primary neurons and N2a cells compared with vehicle treatment at a concentration of 10 μM (Figs. 8B, C and S6D, E). TNT treatment also significantly increased Cend1 dimers and monomer levels by Western blot under nonreducing conditions (Figs. 8D and S6F). However, TNT did not have any impact on Cend1 mRNA expression in cultured primary neurons (Fig. 8E) and N2a cells (Fig. S6G), suggesting that TNT increased Cend1 expression at protein levels. Cend1 dimers in 293 T cells that were exposed to cycloheximide had improved dimer stability after being treated with TNT, as examined under nonreducing Western blot conditions (Fig. S7A, B). In Cend1-G130P-transfected cells, TNT did not improve the stability of Cend1 monomeric mutants (Fig. S7C, D). Interestingly, TNT significantly reduced OGD-induced apoptosis in cultured primary neurons, as measured by the percentage of cleaved caspase-3–positive cells (Fig. 8F, G). To complement this analysis and capture caspase-independent cell death, we also quantified the proportion of condensed nuclei using DAPI staining, which is presented in Fig. 8H. TNT rapidly increased the Cend1 protein levels, which peaked at 1 h (Fig. 8I, J). Both pre-treatment and post-treatment (at 24 h) of TNT significantly reduced the volume of cerebral infarction volume (Fig. 8K, L). However, TNT treatment did not reduce cerebral infarction volume in Cend1 KO mice (Fig. 8M, N), suggesting that the neuroprotection of TNT against ischemic brain injury is dependent on Cend1 protein. Furthermore, an immunoprecipitation assay was performed in ischemic brain tissues after TNT treatment. Relative Atp5f1b protein significantly increased in ischemic brain tissues after TNT treatment compared with the control group (Fig. S8A). Quantitative analysis confirmed the signficant increase of relative immunoprecipitated Atp5f1b with Cend1 in ischemic brain tissues after TNT treatment (Fig. S8B, P < 0.05). Therefore, the data demonstrated that TNT regulates the interaction between Cend1 and Atp5f1b and promotes its neuroprotective effect.Fig. 8TNT protected against cerebral ischemia/reperfusion injury by upregulating the protein level of Cend1.A Chemical structure of TNT was shown. B Cultured primary neurons were treated with vehicle (0.9% NaCl) or TNT (10 μM) for 24 h. Cell lysates were extracted for Western blot analysis to detect Cend1 protein. C Quantitative densitometric analysis of Cend1 protein levels normalized to β-actin was performed. Data are presented as mean ± SEM, N = 5. D Cultured primary neurons were treated with NS or TNT (10 μM) for 24 h. Western blot analysis under non-reducing conditions was used to detect monomers and dimers of Cend1 protein. E Cultured primary neurons were treated with NS or TNT (10 μM) for 24 h, Cend1 mRNA was examined by quantitative PCR analysis. F After primary neurons were cultured for 7 d, the cultured neurons were subjected to OGD/R. TNT was given at 0 h after OGD/R. Immunofluorescence staining was performed with cleaved caspase-3 (Red) in cultured primary neurons with TNT treatment after OGD/R 24 h. G Counts of caspase-3-positive cells in cultured primary neurons after OGD/R treated with NS or TNT were shown. H After primary neurons were cultured for 7 d, the cultured neurons were subjected to OGD/R. TNT was given at 0 h after OGD/R. Counts of condensed nuclei in cultured primary neurons after OGD/R treated with NS or TNT were shown. I Mice were treated with TNT and then the brain tissues were collected at different time points. Cend1 protein was examined by Western blot analysis. J The quantitative analysis of Cend1 protein levels was examined by western blot analysis. N = 6. K C57BL/6 J mice were subjected to MCAO/R. TNT was given (i.p.) at 0 h before MCAO/R (Pre-treatment), 0 h after MCAO/R (Post-treatment-0h), and 4.5 h after MCAO/R (Post-treatment-4.5 h). TTC staining was performed at 24 h after MCAO/R to evaluate the infarct volume in different groups. L The infract volume was quantified and expressed as the percentage of the contralateral hemispheric volume. N = 6. M Cend1 KO mice were given (i.p.) TNT treatment at 0 h after MCAO/R. TTC staining was performed at 24 h after MCAO/R. N The infract volume was determined and expressed as the percentage of the contralateral hemispheric volume. N = 6. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ns, not significant. TNT protected against cerebral ischemia/reperfusion injury by upregulating the protein level of Cend1. A Chemical structure of TNT was shown. B Cultured primary neurons were treated with vehicle (0.9% NaCl) or TNT (10 μM) for 24 h. Cell lysates were extracted for Western blot analysis to detect Cend1 protein. C Quantitative densitometric analysis of Cend1 protein levels normalized to β-actin was performed. Data are presented as mean ± SEM, N = 5. D Cultured primary neurons were treated with NS or TNT (10 μM) for 24 h. Western blot analysis under non-reducing conditions was used to detect monomers and dimers of Cend1 protein. E Cultured primary neurons were treated with NS or TNT (10 μM) for 24 h, Cend1 mRNA was examined by quantitative PCR analysis. F After primary neurons were cultured for 7 d, the cultured neurons were subjected to OGD/R. TNT was given at 0 h after OGD/R. Immunofluorescence staining was performed with cleaved caspase-3 (Red) in cultured primary neurons with TNT treatment after OGD/R 24 h. G Counts of caspase-3-positive cells in cultured primary neurons after OGD/R treated with NS or TNT were shown. H After primary neurons were cultured for 7 d, the cultured neurons were subjected to OGD/R. TNT was given at 0 h after OGD/R. Counts of condensed nuclei in cultured primary neurons after OGD/R treated with NS or TNT were shown. I Mice were treated with TNT and then the brain tissues were collected at different time points. Cend1 protein was examined by Western blot analysis. J The quantitative analysis of Cend1 protein levels was examined by western blot analysis. N = 6. K C57BL/6 J mice were subjected to MCAO/R. TNT was given (i.p.) at 0 h before MCAO/R (Pre-treatment), 0 h after MCAO/R (Post-treatment-0h), and 4.5 h after MCAO/R (Post-treatment-4.5 h). TTC staining was performed at 24 h after MCAO/R to evaluate the infarct volume in different groups. L The infract volume was quantified and expressed as the percentage of the contralateral hemispheric volume. N = 6. M Cend1 KO mice were given (i.p.) TNT treatment at 0 h after MCAO/R. TTC staining was performed at 24 h after MCAO/R. N The infract volume was determined and expressed as the percentage of the contralateral hemispheric volume. N = 6. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ns, not significant. To investigate whether TNT exerts neuroprotective effects by modulating mitochondrial function, HEK293T cells were subjected to OGD/R in vitro, followed by TNT treatment. As shown in Fig. 9A, B, TNT treatment reduced the proportion of JC-1 monomers, suggesting a relative increase in mitochondrial membrane potential (ΔΨm). Similarly, TNT enhanced calcein-AM fluorescence under OGD/R conditions, indicating a tendency to inhibit mPTP opening (Fig. 9C, D). Although an upward trend was observed in NADH–CoQ reductase activity, the difference did not reach statistical significance (Fig. 9E). Importantly, TNT significantly increased F₁F-ATP synthase activity and maintained higher intracellular ATP levels after OGD/R (Fig. 9F, G). These findings suggest that, under ischemic stress, TNT may help preserve mitochondrial integrity and functional capacity, potentially contributing to its neuroprotective effects.Fig. 9HEK293T cells were subjected to oxygen-glucose deprivation/reperfusion (OGD/R) and immediately treated with TNT.Cells were collected 24 h after reperfusion for subsequent assays. A Cells were stained with JC-1 at working concentration, and the ratio of JC-1 monomers to aggregates was analyzed by flow cytometry. B Quantification of JC-1 monomer proportion. N = 3. C Cells were stained with MPTP detection reagent at working concentration, and green fluorescence intensity was analyzed by flow cytometry. D Quantification of green fluorescence intensity reflecting mPTP opening. N = 3. E NADH–CoQ reductase activity was measured using a mitochondrial complex I activity assay kit according to the manufacturer’s instructions, and relative activity was quantified. N = 3. F F₁F₀-ATP synthase activity was measured using a complex V activity assay kit and quantified as relative activity. N = 3. G Intracellular ATP content was measured using a luminescence-based ATP assay kit and quantified relative to control. N = 3. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ns, not significant. HEK293T cells were subjected to oxygen-glucose deprivation/reperfusion (OGD/R) and immediately treated with TNT. Cells were collected 24 h after reperfusion for subsequent assays. A Cells were stained with JC-1 at working concentration, and the ratio of JC-1 monomers to aggregates was analyzed by flow cytometry. B Quantification of JC-1 monomer proportion. N = 3. C Cells were stained with MPTP detection reagent at working concentration, and green fluorescence intensity was analyzed by flow cytometry. D Quantification of green fluorescence intensity reflecting mPTP opening. N = 3. E NADH–CoQ reductase activity was measured using a mitochondrial complex I activity assay kit according to the manufacturer’s instructions, and relative activity was quantified. N = 3. F F₁F₀-ATP synthase activity was measured using a complex V activity assay kit and quantified as relative activity. N = 3. G Intracellular ATP content was measured using a luminescence-based ATP assay kit and quantified relative to control. N = 3. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ns, not significant. Discussion In this study, Cend1 was first determined to be predominantly localized within the mitochondria, where it plays a key role in maintaining mitochondrial function. Cend1 dimerization was confirmed as essential for regulating ATP production, with two highly conserved GXXXA motifs in its transmembrane domain, specifically G130 and G141, serving as critical dimerization sites. More importantly, Cend1 was shown to interact with the mitochondrial protein Atp5f1b, which plays a significant role in ATP synthesis, further highlighting the importance of this interaction in regulating mitochondrial function. Subsequent screening of small molecular compounds identified TNT as a potential therapeutic agent targeting the Cend1/Atp5f1b interaction, suggesting its effectiveness in treating ischemic stroke. Overall, these findings emphasize that modulating the Cend1/Atp5f1b interaction to enhance ATP production could provide a promising therapeutic strategy for reducing ischemic injury and supporting recovery. Cend1 is a neuron-specific protein that was initially discovered to be expressed in the striatum neurons of pigs but not in glial cells27. It is a type-I single transmembrane protein with a short tail consisting of three positively charged residues (RKK) at the C-terminal. This unique structure allows most proteins to face the cytoplasm, which has been proven to be essential for Cend1 to correctly target the outer mitochondrial membrane28. Through purification and characterization, it has been determined that Cend1 is an integral membrane protein, lacking glycosylation, and composed of two identical polypeptide chains connected by disulfide bonds13,29. In this study, it was demonstrated that the GXXXA motif serves as a key protein dimerization motif in the formation of Cend1 dimers. Notably, G130 was identified as the critical site for Cend1 dimerization using amino acid point mutation technology. Furthermore, overexpression of the Cend1 protein leads to an increase in intracellular ATP levels, indicating its role in regulating energy metabolism. However, the G130P mutant, which disrupts the dimerization, fails to regulate ATP levels. This highlights the importance of Cend1 dimerization for its function in mitochondria. It is well-established that the dimerization of mitochondrial proteins is essential for their proper functioning. For example, CIDE-B induces apoptosis by targeting mitochondria and forming homo-dimeric or heterodimeric complexes30. Similarly, defects in the dimerization of FoF1-ATP synthase in myocardial cells of aging mice result in abnormal mitochondrial cristae tip curvature and impaired oxidative phosphorylation efficiency31. Consistent with this, our OGD/R experiments show that the neuroprotective effects of TNT, including preservation of ΔΨm and ATP levels, depend on Cend1, as these effects are lost when Cend1 is absent. Instead of focusing on the role of dimers in the maintenance of normal mitochondrial function, it was found that the stability of Cend1 dimers is significantly greater than that of Cend1 monomers. Interestingly, the G130P mutant disrupts the dimerization of Cend1 and promotes accelerated degradation of Cend1 monomers. This parallels findings in other studies, such as the acetylation-dependent degradation of monomeric FUNDC1 through the proteasome pathway upon its transition from a dimer to a monomer32. Therefore, the dimerization of Cend1 is crucial for its proper function in mitochondria and the regulation of energy metabolism. Exploring the complex mechanisms involved in Cend1 dimerization and its impact on cellular processes may contribute to a better understanding of mitochondrial biology and potential therapeutic targets for associated disorders. Endogenous Cend1 levels rise during cerebral ischemia/reperfusion, reflecting an intrinsic compensatory response that is insufficient to prevent injury. Experimental overexpression produces higher and more sustained Cend1 expression, which enhances neuronal survival and reduces infarct size. Both loss- and gain-of-function experiments reported here support this interpretation, demonstrating that elevated Cend1 confers protection rather than harm. Previous work also found that Cend1 overexpression in neural progenitor cells promotes neuronal differentiation and limits astrocytic scar formation in cortical injury models33. Importantly, these protective effects depend on the ability of Cend1 to form stable dimers, as disruption of dimerization (e.g., G130P mutation) abolishes its regulation of ATP levels and compromises mitochondrial function. Collectively, these data indicate that ischemia-driven Cend1 upregulation is an endogenous rescue attempt that falls short of a protective threshold, whereas therapeutic augmentation of Cend1—particularly in its dimeric form—can push the response into a neuroprotective range and facilitate brain repair. To further investigate how Cend1 regulates energy metabolism in mitochondria, IP-MS/MS was conducted and identified Atp5f1b as an essential subunit of the mitochondrial ATP synthase complex interacting with Cend134. The mitochondrial ATP synthase complex is responsible for synthesizing the primary energy currency, ATP35. Atp5f1b is encoded by a nuclear gene and is assembled with other subunits encoded by either mitochondrial or nuclear genes to form the ATP synthase complex34. This complex functions to convert ADP and inorganic phosphate into ATP by utilizing the proton gradient across the mitochondrial inner membrane36. Under the ischemic condition, Cend1 levels increase and associate with Atp5f1b to form a protein complex, whereas Cend1 deficiency leads to reduced ATP production. These findings suggest that the interaction between Cend1 and Atp5f1b may enhance or modulate ATP synthase efficiency and influence ATP production. The Cend1/Atp5f1b interaction may play a role in ATP synthesis by influencing the assembly and activity of the ATP synthase complex. Dysfunction of this interaction could impair oxidative phosphorylation (OXPHOS), leading to reduced mitochondrial ATP production. These results offer insight into mitochondrial energy regulation and highlight potential therapeutic targets for neurological disorders associated with mitochondrial dysfunction. Considering that the Cend1/Atp5f1b interaction influences ATP production and may contribute to cellular protection in ischemic stroke, a small molecule compound was screened to increase Cend1 expression in cells using ICW technology. Among these small compounds, TNT significantly increased Cend1 expression in cells after treatment. TNT was previously reported as a tricyclic antidepressant, which regulates the level of neurotransmitters by increasing the uptake of 5-hydroxytryptamine (5-HT) in synaptic cleft for treatment37,38. The study demonstrated that TNT alleviated the injury caused by ischemic stroke. However, our data demonstrated that the neuroprotective effect of TNT was abolished when Cend1 was knocked out in mice. This indicates that the protection of TNT on ischemic cerebral injury was dependent on cellular Cend1. Further findings showed that TNT increased the interaction between Cend1 and Atp5f1b after ischemic injury. Given that Atp5f1b is a subunit of the ATP synthase complex and plays a critical role in ATP production34, the administration of TNT is expected to enhance ATP synthesis following cerebral ischemic injury, which our results confirmed. In OGD/R models, TNT treatment increased mitochondrial membrane potential (ΔΨm), enhanced ATP synthase activity, and raised ATP levels, whereas its neuroprotective effect was abolished in the absence of Cend1. Therefore, targeting the Cend1/Atp5f1b interaction using TNT could be a potential strategy for treating ischemic stroke. Further research is needed to investigate the specific regulatory effect of TNT on the Cend1/Atp5f1b interaction and to evaluate its safety and efficacy in clinical applications for ischemic stroke patients. We verified fraction purity in Fig. 1A using Tom20 and β-actin, which showed minimal mitochondrial breakage, but minor contamination from other compartments cannot be fully excluded. Different internal controls were applied across experiments, which may lead to minor variability. Future studies will consider the use of both total protein normalization and compartment-specific markers to further enhance the reliability of Western blot analyses. Although we performed additional assays (ΔΨm, mPTP opening, ATP content, Complex I and V activities) to assess mitochondrial function, the mechanistic role of Cend1 in directly regulating ATP synthase activity versus its structural role in mPTP formation under ischemic conditions remains to be clarified. Future studies will focus on these aspects to comprehensively elucidate Cend1’s role in post-injury brain repair and recovery. In this study, it was demonstrated for the first time that dimerized Cend1 proteins regulate mitochondrial functions through interaction with Atp5f1b following cerebral ischemic injury. This interaction results in increased intracellular ATP levels and enhanced mitochondrial function. Additionally, small molecular compounds such as TNT were identified to elevate Cend1 expression in cells, indicating their potential as therapeutic agents for ischemic stroke (Fig. 10). Consequently, targeting the Cend1/Atp5f1b interaction may represent a promising therapeutic strategy for diseases characterized by mitochondrial dysfunction, including stroke, Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.Fig. 10Schematic diagram showed the protective mechanisms of Cend1 against ischemia-reperfusion (I/R) injury.During cerebral ischemia/reperfusion injury, Cend1 expression is transiently upregulated as an endogenous protective response. Cend1 forms stable dimers on the outer mitochondrial membrane and interacts with Atp5f1b, helping to preserve mitochondrial function and support ATP synthesis. However, as injury progresses, this short-lived increase in endogenous Cend1 becomes insufficient to effectively counteract mitochondrial dysfunction. TNT treatment further elevates Cend1 expression and enhances its interaction with Atp5f1b, thereby strengthening mitochondrial protection and contributing to improved neuronal survival. Schematic diagram showed the protective mechanisms of Cend1 against ischemia-reperfusion (I/R) injury. During cerebral ischemia/reperfusion injury, Cend1 expression is transiently upregulated as an endogenous protective response. Cend1 forms stable dimers on the outer mitochondrial membrane and interacts with Atp5f1b, helping to preserve mitochondrial function and support ATP synthesis. However, as injury progresses, this short-lived increase in endogenous Cend1 becomes insufficient to effectively counteract mitochondrial dysfunction. TNT treatment further elevates Cend1 expression and enhances its interaction with Atp5f1b, thereby strengthening mitochondrial protection and contributing to improved neuronal survival. Ethics approval and consent to participate The animal studies protocols were approved by the Ethics Committee of the Fourth Affiliated Hospital of Soochow University and its institutional animal-care committee with Protocol numbers (241030). Supplementary information Supplementary Information Description of Additional Supplementary Files Supplementary Data 1 Reporting Summary Supplementary Information Description of Additional Supplementary Files Supplementary Data 1 Reporting Summary